KR20240127992A - 항-돌연변이 칼레티쿨린(calr) 항체 및 이의 용도 - Google Patents

항-돌연변이 칼레티쿨린(calr) 항체 및 이의 용도 Download PDF

Info

Publication number
KR20240127992A
KR20240127992A KR1020247022555A KR20247022555A KR20240127992A KR 20240127992 A KR20240127992 A KR 20240127992A KR 1020247022555 A KR1020247022555 A KR 1020247022555A KR 20247022555 A KR20247022555 A KR 20247022555A KR 20240127992 A KR20240127992 A KR 20240127992A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antibody
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022555A
Other languages
English (en)
Korean (ko)
Inventor
패트릭 메이스
호라시오 지. 나스트리
레베카 에이. 부온판
에디마라 에스. 레이스
숀 엠. 스튜어트
징 저우
마르크 시. 델러
샹-팅 레이
레슬리 브룩 에플링 맥퀴어터
융훙 자오
함자 세릭
브리트니 멜리사 와스
Original Assignee
인사이트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인사이트 코포레이션 filed Critical 인사이트 코포레이션
Publication of KR20240127992A publication Critical patent/KR20240127992A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/57496—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247022555A 2021-12-08 2022-12-07 항-돌연변이 칼레티쿨린(calr) 항체 및 이의 용도 Pending KR20240127992A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163287394P 2021-12-08 2021-12-08
US63/287,394 2021-12-08
US202163288479P 2021-12-10 2021-12-10
US63/288,479 2021-12-10
US202263421052P 2022-10-31 2022-10-31
US63/421,052 2022-10-31
PCT/US2022/081076 WO2023107994A1 (en) 2021-12-08 2022-12-07 Anti-mutant calreticulin (calr) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20240127992A true KR20240127992A (ko) 2024-08-23

Family

ID=84943209

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022555A Pending KR20240127992A (ko) 2021-12-08 2022-12-07 항-돌연변이 칼레티쿨린(calr) 항체 및 이의 용도

Country Status (19)

Country Link
US (1) US20230272055A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444343A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500796A (cg-RX-API-DMAC7.html)
KR (1) KR20240127992A (cg-RX-API-DMAC7.html)
AU (1) AU2022407445A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241889A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024001654A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009042A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240277A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000110A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416555A (cg-RX-API-DMAC7.html)
IL (1) IL313366A (cg-RX-API-DMAC7.html)
JO (1) JOP20240122A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024006954A (cg-RX-API-DMAC7.html)
PE (1) PE20241998A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330623A (cg-RX-API-DMAC7.html)
UY (1) UY40062A (cg-RX-API-DMAC7.html)
WO (1) WO2023107994A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202404295B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
WO2025096716A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof
WO2026013015A1 (en) * 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026136827A1 (en) 2024-12-20 2026-06-25 Incyte Corporation Treatment of clonal hematopoietic disorders using kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3932952A4 (en) 2019-02-28 2022-11-30 Juntendo Educational Foundation ANTIBODIES BINDING TO TRUNKED MUTANT CALRETICULIN AND DIAGNOSTIC, PROPHYLACTIC OR THERAPEUTIC DRUG FOR MYELOPROLIFERATIVE NEOPLASMA

Also Published As

Publication number Publication date
PE20241998A1 (es) 2024-09-27
US20230272055A1 (en) 2023-08-31
UY40062A (es) 2023-06-30
DOP2024000110A (es) 2024-09-30
CL2024001654A1 (es) 2024-11-04
GEAP202416555A (en) 2024-10-28
TW202330623A (zh) 2023-08-01
CO2024009042A2 (es) 2024-08-08
EP4444343A1 (en) 2024-10-16
MX2024006954A (es) 2024-06-21
JP2025500796A (ja) 2025-01-15
JOP20240122A1 (ar) 2024-05-29
CL2025000229A1 (es) 2025-06-06
IL313366A (en) 2024-08-01
AU2022407445A1 (en) 2024-06-13
CR20240277A (es) 2024-08-07
WO2023107994A1 (en) 2023-06-15
CA3241889A1 (en) 2023-06-15
ZA202404295B (en) 2025-02-26

Similar Documents

Publication Publication Date Title
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
CN111182919B (zh) 抗cd137抗体
CA2597717C (en) Antibodies against cxcr4 and methods of use thereof
EP4084825A1 (en) Anti-cd73 antibodies and uses thereof
US20230272055A1 (en) Anti-mutant calreticulin (calr) antibodies and uses thereof
AU2016200412A1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
JP2022502024A (ja) 抗ヒトcd45rc抗体及びその使用
KR20250153216A (ko) Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
US20250084177A1 (en) Anti-cd98 antibodies and uses thereof
KR20230142530A (ko) 항체-약물 접합체 및 이의 의학적 용도
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
CN104379603A (zh) Tlr3结合剂
WO2015169811A2 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
CN112041346A (zh) 用于与抗pd-1抗体组合的抗cd137抗体
JP2024177124A (ja) 抗変異体カルレチクリン(calr)抗体及びその使用
US20250090659A1 (en) Combination therapy with an anti-cd19 antibody and parsaclisib
CN118591386A (zh) 抗突变体钙网蛋白(calr)抗体及其用途
CN112020517A (zh) 用于与抗pd-l1抗体组合的抗cd137抗体
US20240109971A1 (en) Ccr6 antibodies
CN116410326A (zh) 抗cd40×cldn18.2双特异性抗体及其用途
US12421307B2 (en) Anti-FGF19 antibodies
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN111094337A (zh) 与K-Ras基因状态有关的CK8阳性癌症的治疗
CN120225553A (zh) 抗β-连环蛋白抗体
WO2025171447A1 (en) Antibodies for binding ccr6

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000